DIAGNOS Welcomes Veteran Optometrist Dr. Barry A. Ginsberg to its Scientific Advisory Board for the United States
MWN-AI** Summary
DIAGNOS Inc., a leader in early detection of health issues via Artificial Intelligence (AI), announced the appointment of Dr. Barry A. Ginsberg, O.D., to its Scientific Advisory Board. Based in Brossard, Quebec, DIAGNOS (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) aims to enhance diagnostic accuracy in optometry through advanced technology. Dr. Ginsberg, with over 30 years of diverse practice in corporate, retail, and private settings, brings substantial insights into the U.S. optical market.
Teaming up with influential figures such as Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, and seasoned entrepreneur Ed Weiner, Dr. Ginsberg will leverage his extensive experience to refine DIAGNOS's market strategies. His expertise includes innovative product launches, advanced contact lens fitting, and ocular disease management, which are critical as the company seeks to demonstrate the ROI of AI-driven screening to both investors and practitioners.
Dr. Ginsberg holds a B.A. in Chemistry and a Doctor of Optometry from the Pennsylvania College of Optometry, with specialized externships in age-related macular degeneration and glaucoma. President and CEO André Larente noted that Dr. Ginsberg’s ability to convert clinical value into business outcomes is pivotal as DIAGNOS expands its presence within the optical marketplace.
The company has recently established a U.S. office in south Florida to better engage with American clients, capitalizing on the significant demand reflected in VisionWatch data, which reported around 111 million routine eye exams and 60 million medical eye exams in 2020. With plans to address this growing market, DIAGNOS continues to innovate and enhance patient outcomes through AI technology. For further insights into their initiatives, visit www.diagnos.com.
MWN-AI** Analysis
DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) is making strategic strides in the optical market with the recent appointment of Dr. Barry A. Ginsberg to its Scientific Advisory Board. His extensive experience in optometry and track record of launching innovative products position DIAGNOS favorably as it looks to enhance its Artificial Intelligence-driven healthcare solutions.
As DIAGNOS expands its presence in the U.S. market, notably with the opening of a Florida office, the company appears well-positioned to leverage the substantial demand for eye examinations in the country. With an estimated 111 million routine eye exams and 60 million medical exams conducted in the U.S. in 2020, there is a clear opportunity for DIAGNOS’s CARA AI platform in enhancing diagnostic practices and patient outcomes. Investors should note this growth potential, especially as the healthcare sector increasingly seeks integrated technology solutions to improve efficiency and accuracy.
The combination of Dr. Ginsberg’s clinical insights and the existing expertise of Mr. Ed Weiner and Dr. Tomas J. Philipson on the advisory board is likely to amplify DIAGNOS's credibility within the industry. Their collective knowledge will assist in refining marketing strategies and demonstrating the ROI of AI applications, which is crucial in persuading healthcare providers to adopt DIAGNOS’s technologies.
Investors should consider the evolving healthcare landscape where AI solutions are gaining traction. DiagNOS’s commitment to early detection aligns with broader industry trends towards preventative health measures, making it a player to watch. However, as always, potential investors should exercise caution and conduct thorough due diligence, especially considering the general volatility in technology-driven healthcare stocks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROSSARD, Quebec, June 25, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence ( AI ), is thrilled to announce that Dr. Barry A. Ginsberg, O.D. has joined the Corporation’s Advisory Board.
Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers and Mr. Ed Weiner, a seasoned entrepreneur, to provide valuable insights to DIAGNOS about the US optical market.
Dr. Ginsberg brings more than three decades of practice across corporate, retail and private-practice settings, giving him a ground-level view of how new technologies gain traction in high-volume optometry environments. He has repeatedly identified and launched innovative products and services that increased revenue per visit and improved patient retention for leading optical chains. This commercial experience, combined with his expertise in advanced contact-lens fitting and ocular-disease management, will help DIAGNOS refine its go-to-market strategy and demonstrate the tangible ROI of AI-driven screening to investors and practitioners alike.
Dr. Ginsberg earned a B.A. in Chemistry with a minor in Economics from Yeshiva University, followed by a B.S. and Doctor of Optometry from the Pennsylvania College of Optometry. His training included an externship at the Feinbloom Low Vision Center in Philadelphia, where he focused on age-related macular degeneration, and another at the Goldschleger Eye Institute in Tel Hashomer Hospital, Israel, where he concentrated on glaucoma and other ocular diseases.
President and CEO André Larente noted that Dr. Ginsberg’s “ability to translate clinical value into business outcomes makes him an ideal partner as we expand CARA into the wider optical marketplace.” Mr. Larente added, “DIAGNOS has built an AI platform to analyze retina images, these images are taken by thousands of optometrists worldwide. According to recent VisionWatch data, the US saw approximately 111 million routine eye exams and 60 million medical eye exams in 2020. DIAGNOS, along with its partners can address this growing market”.
DIAGNOS recently opened its US office in south Florida to support its US prospects and clients.
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
Additional information is available at www.diagnos.com and www.sedarplus.com .
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450-678-8882 ext. 224alarente@diagnos.caDr. Sidharth Mehta, MDAllele Capital PartnersTel: 732-259-6728smehta@allelecapital.com
FAQ**
How does Dr. Barry A. Ginsberg's experience in the optical market specifically enhance the commercialization strategy for Diagnos Inc. ADK:CC in the competitive AI-driven healthcare landscape?
What metrics will Diagnos Inc. ADK:CC use to measure the ROI of their AI-driven screening solutions as they expand into the US optical market under Dr. Ginsberg's advisory?
With the recent opening of a US office, what specific strategies does Diagnos Inc. ADK:CC have in place to attract clients and partnerships in the growing US optical market?
Considering the significant number of routine and medical eye exams, what role will AI technology play in improving diagnostic accuracy and patient outcomes for Diagnos Inc. ADK:CC in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Diagnos Inc. (TSXVC: ADK:CC).
NASDAQ: ADK:CC
ADK:CC Trading
0.0% G/L:
$0.22 Last:
18,502 Volume:
$0.22 Open:
